Collect whole blood in a purple top (EDTA) tube (preferred).
5 ml whole blood or 1 ug extracted DNA
3 ml whole blood
Refrigerate sample until shipment. Send the sample at room temperature with overnight delivery for receipt Monday through Friday within 24 hours of collection.
Whole blood can be refrigerated until shipment.
Heparinized specimens, severely hemolyzed specimens, frozen, clotted or possibly commingled specimens, blood in non-sterile or leaky containers, mislabeled or inappropriately labeled specimens.
Do not heat, freeze or centrifuge blood before shipment. Refrigerate sample until shipment.
Mon - Fri 9:00am to 4:00pm
Hereditary leiomyomatosis and renal carcinoma is a form of inherited kidney cancer due to mutations in the fumarate hydratase gene. Affected individuals develop benign smooth muscle tumors of the skin; affected females frequently develop leiomyomata of the uterus (fibroids). Tumors typically present at 20-35 years of age, although the phenotype can be subtle and penetrance may be incomplete. Predisposition to type II papillary renal cell carcinoma has been observed in some families.
The FH gene is located on chromsome1q42.1. The inheritance pattern is autosomal dominant. The mutations are predicted to result in absent or truncated proteins or in non-conservative substitutions in highly conserved amino acid residues. Missense, nonsense, splice site, small insertions and deletions and large deletions of the entire coding region have been identified in affected individuals.
Sequence analysis of the mutation previously identified in a family member will be performed.
The analytical sensitivity is close to 100% for known point mutations using DNA sequencing.The analytical sensitivity is greater than 99% for whole gene deletions using MLPA.
Test results with interpretation will be mailed and/or faxed to the referring physician or send out lab following completion of the test. Additional reports will be provided as requested.
To identify patients with benign skin nodules and/or uterine fibroids who might be at increased risk for papillary type II renal cell carcinoma in order to facilitate clinical screening of the patient and molecular analysis of other at risk relatives.
Ask for more information about our laboratory services.